NLRP3 and brain infarction: In vivo results demonstrated that treatment with ruscogenin (10 mg/kg) could reduce brain infarction volume and edema and improve neurological deficits, histopathological damage, and CBF in MCAO/R-injured mice, and these effects might be related to its ability to ameliorate BBB breakdown and suppress TXNIP/NLRP3 inflammasome activation (Figure 1, Figure 2, Figure 3 and Figure 4).